Key Takeaways
- Biogen is downsizing its research team to enhance drug discovery capabilities and ensure sustainable growth.
- Changes include leadership restructuring, with new heads for key divisions like biomarkers, immunology research, and system biology.
- These developments come after Biogen’s significant layoffs last year and amid ongoing legal tensions with partner Sage Therapeutics.
Biogen Restructures Research Team Amid Leadership Changes
Jane Grogan, Ph.D., has initiated significant changes in Biogen’s research department just over a year into her tenure. This restructuring follows substantial employee layoffs and aims to revitalize the company’s drug discovery capabilities while ensuring long-term growth. A spokesperson for Biogen confirmed these changes and noted that the specific number of layoffs has not been disclosed.
The shifts in the research department are designed to align the organization more closely with its prioritized preclinical portfolio and to pivot resources towards external opportunities. This decision stems from a comprehensive assessment of Biogen’s research capabilities, considering the rapidly evolving landscape of innovation.
Accompanying these layoffs are notable changes in leadership. Danielle Graham, Ph.D., who previously served as the interim head of translational medicine, has been appointed the head of biomarkers and system biology. In addition, Nick Wilson, Ph.D., joins Biogen from Bristol Myers Squibb, where he was vice president of cancer immunology and cell therapy. Wilson will now lead Biogen’s immunology research efforts, bringing substantial experience as he transitions into his new role.
Grogan took charge of Biogen’s research division in October 2023, following a significant restructuring that resulted in the loss of over 1,000 jobs. Her approach to leading the research team has been described as akin to running a “scrappy startup,” reflecting a dynamic and agile management style.
In light of recent events, Biogen has faced external challenges as well. The company has been embroiled in legal disputes with Sage Therapeutics, a longstanding partner. Sage filed a lawsuit after receiving an unsolicited buyout offer from Biogen, which adds an element of complexity to their ongoing collaboration. This partnership initially emerged in 2020 for the development of zuranolone and other pipeline candidates.
Overall, the latest changes at Biogen illustrate a strategic response to both internal assessments of research capabilities and external pressures in a competitive biotech environment. As the company navigates through workforce reductions and management shifts, the focus remains keenly set on enhancing innovation and ensuring future growth.
The content above is a summary. For more details, see the source article.